Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. - Wikidata - awgldk - TriplyDB

Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

http://www.wikidata.org/entity/Q34749432

about

Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.Hematological and biochemical data obtained in rural northern Uganda.Recent advances in recombinant protein-based malaria vaccines.Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA Progress and prospects for blood-stage malaria vaccines Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery.The path of malaria vaccine development: challenges and perspectives.Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates.Safety, immunogenicity, and cross-species protection of a plasmid DNA encoding Plasmodium falciparum SERA5 polypeptide, microbial epitopes and chemokine genes in mice and olive baboons.Vaccines to Accelerate Malaria Elimination and Eventual Eradication.Vaccine candidates for malaria: what's new?Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5.

P2860

Q26772878-CEBF9E9E-22C9-4807-BABF-08D4CB70DB69 Q30363119-6EF089F6-CB04-444B-A414-33A212AA8E08 Q30815803-654BA240-4F92-44EA-B844-55D74F01F038 Q36394182-C492527A-0E9F-4C18-8603-112FE9283BBE Q36687352-285793A6-5DB8-4863-85CE-A97FB9A794E8 Q37025030-7695B5BA-45EA-4070-ABF5-E9F8C6FF913C Q37310848-CCE4BDB6-D988-4FD7-AC0F-1B13C699650C Q38168906-D06BF809-1275-4391-B726-CF244D072E4B Q38196455-A17D043D-FAA6-434E-AFF8-E1DD6799D207 Q38672088-E1596BBD-0D55-4561-B643-EF9E8D66D359 Q38849255-CBF4CD7D-C444-4C39-A573-1256A0ECBC87 Q39296506-14B76A58-A774-4108-B004-0973B3A68FA3 Q47935989-75177B7D-C7CD-4E12-AE28-A744C597407B Q52724844-72CC81C8-8E36-4CF2-81CF-7301A8A4C2F6

P2860

Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

http://www.wikidata.org/entity/Q34749432

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@ast

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@en

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@nl

type

label

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@ast

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@en

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@nl

prefLabel

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@ast

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@en

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@nl

P1433

Q34749432-1187D41B-E430-4AA2-B02E-0089BB0340F2

P1476

Q34749432-CA4AA711-DFFF-4357-B6D2-E2AD2A8AFB1D

P2093

Q34749432-06138A1C-6D0F-4D11-962A-AE2C96CEA1EB

Q34749432-175CC3DA-F767-4133-BCCF-3DCBFADE86EB

Q34749432-24492B3A-99FC-49A1-B67C-42B018608716

Q34749432-435A365E-DE30-4D78-963A-452F3B71AC9A

Q34749432-5A6563F6-7758-41AA-B4C2-1D86C24C2387

Q34749432-5ADB2DFD-D175-4BAD-8B2D-772AB65EC45F

Q34749432-66200A88-23B5-4809-ADFB-840E2A60B628

Q34749432-7543514C-7D00-4638-8AF4-E11BF9DD239E

Q34749432-7CA37FE7-63BF-4808-BE77-ABCAD457E407

Q34749432-AD843BB9-F884-4542-B5F6-9C4DEB403166

P2860

Q34749432-24884D63-1557-4A9A-BC5F-CE4871C2B0E1

Q34749432-25867DF9-907D-4FCA-A3EA-B8EBF8B1916D

Q34749432-2D1AF2ED-DD5A-4E1A-8B93-A164506F3B23

Q34749432-327FE337-3461-495C-81C7-49E6F8EDD50B

Q34749432-4391FB9F-5524-4214-8748-8EE2E7558C21

Q34749432-456ED813-9301-493B-88AB-9DD68DBBECD1

Q34749432-4D8DFBC5-F9CD-45A1-A517-58CECD1F1B86

Q34749432-4FA5B588-BFEF-4BC7-9349-68A2E327A160

Q34749432-54914BAB-4CB9-4871-8F29-377C9001B6B9

Q34749432-55951D77-A2A1-4A14-BC45-559E84C2DA87

P304

Q34749432-80C82BFF-EB81-4218-A5FD-1EF79316DEB5

P31

Q34749432-E10D5B83-7D48-4DE2-8FC1-C7A14FE0D637

P356

Q34749432-12732D20-7B34-42F8-8B96-9D10D635152C

P407

Q34749432-1DB46C9A-EBD0-449C-958B-57E35277CFCE

P433

Q34749432-13E6945E-BD76-4396-A790-E5F7BFC98D4B

P478

Q34749432-0CE8323B-6EF8-46A5-B53F-7F5E8BF784C3

P50

Q34749432-09A79CD6-662A-42C1-8829-F3BFB860FE8F

Q34749432-565864A5-D0BA-4B01-AB3D-268A94B57B01

Q34749432-9ABAA06F-9118-440C-967A-4374BB87B9BE

Q34749432-DF2CEADD-AB4C-4A49-9425-C62D16E0C050

Q34749432-F968BD94-4B37-459D-BB13-926AFF55F199

P577

Q34749432-08EE4160-3123-413C-B6E0-B14A0D438D27

P5875

Q34749432-688FDE8B-0AE2-4D4F-83FB-77CE8A47A64F

P698

Q34749432-C0F51DF6-8CA9-44CD-A420-79D5D4AD319F

P921

Q34749432-49EC2DD7-402A-4E05-8487-EA274AA25B25

Q34749432-FC8E8CFE-E993-4742-A826-07C1A35A0A39

P932

Q34749432-13AB6507-123B-4C47-9F56-391308610D4E

P356

JOURNAL.PONE.0064073

P1433

P1476

Phase 1b randomized trial and ...... ria vaccine candidate BK-SE36.

@en

P2093

Adoke Yeka

http://www.w3.org/2001/XMLSchema#string

Christopher Nsereko

http://www.w3.org/2001/XMLSchema#string

Edward Ntege

http://www.w3.org/2001/XMLSchema#string

Hiroki Shirai

http://www.w3.org/2001/XMLSchema#string

Kazuya Ito

http://www.w3.org/2001/XMLSchema#string

Kohhei Tetsutani

http://www.w3.org/2001/XMLSchema#string

Masanori Yagi

http://www.w3.org/2001/XMLSchema#string

Nahoko Suzuki

http://www.w3.org/2001/XMLSchema#string

Nobuko Arisue

http://www.w3.org/2001/XMLSchema#string

Sawako Itagaki

http://www.w3.org/2001/XMLSchema#string

P2860

Global malaria mortality between 1980 and 2010: a systematic analysis

Advances and challenges in malaria vaccine development

A review of malaria vaccine clinical projects based on the WHO rainbow table

A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes

Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

P304

e64073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0064073

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Bernard N Kanoi

Nirianne Marie Q Palacpac

Betty Balikagala

Toshihiro Horii

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236978576

http://www.w3.org/2001/XMLSchema#string

P698

23724021

http://www.w3.org/2001/XMLSchema#string

P921

P932

3665850

http://www.w3.org/2001/XMLSchema#string